CA-DEGREED
23.6.2022 21:15:12 CEST | Business Wire | Press release
Degreed , the global innovator in professional lifelong learning chosen by more than one in three Fortune 50 companies, today announced the acquisition of talent academy platform, Learn In , and the return of Co-founder David Blake as CEO. Blake was previously the Co-founder and CEO of Learn In.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220623005917/en/
Learn In helps companies establish internal talent academies that bring together all the resources needed for building a highly skilled workforce, including the longer journey of developing deep skills. Learn In’s core features supplement those of the category-defining Degreed LXP (Learning Experience Platform), including a prepaid learning stipend card, a world-class skills marketplace and custom program builder, a tuition benefits manager, and dedicated coaching.
“A corporate capability academy goes beyond ‘a library of content,’” said global industry analyst and CEO of the Josh Bersin Company, Josh Bersin . “It’s a place people go to advance their job-related capabilities. It goes beyond technical and functional skills and focuses on the real business capabilities a company needs to thrive.”
Degreed plus Learn In will unify the broader range of development options people use, spanning daily learning to long-term upskilling for individual career growth and innovation within organizations.
Blake’s plans for the future of Degreed were divergent with the current direction, so an amicable decision was made that he return to the company as CEO and execute that vision.
Degreed thanks Dan Levin for the progress he has driven and his stewardship of the Degreed mission over the past 15 months, and is grateful for his accomplishments, including increasing our client base, establishing operational rigor for scale, and significantly expanding our partner ecosystem and overall global footprint.
“Businesses that can quickly build effective talent are the ones that will be able to deliver on strategic business goals,” said David Blake, Co-founder and CEO of Degreed . “Just as Degreed created the LXP market, Learn In has begun for talent academies. Now together, we have the product and technology to help our customers deliver business capabilities at scale with continued innovation in the learning and skills space.”
“At BMO, our strategy is to build a digitally-enabled bank that’s ready for the future. This means we need to equip employees with the skills they need for their job, their career, for the future of work, and as they follow their personal passions,” says Gina Jeneroux, Chief Learning Officer at BMO Financial Group . “As Degreed and Learn In come together, it will offer a more integrated opportunity for organizations like ours to engage employees and build a broader range of skills—from curious, ‘in-the-moment’ learning through to deeper reskilling and credentials.”
This is the fourth acquisition for Degreed, and Blake re-joins a seasoned Degreed leadership team from Bank of America, Mastercard, Danone, LinkedIn, Adobe, SAP and Saba.
About Degreed
Degreed empowers innovation through learning. As a changemaker on a global scale, we work with one in three Fortune 50 companies to spark a culture of learning across their enterprise. In one fluid experience, we help you identify the skills you have and build the skills you need – through individual, collaborative and experiential modes of learning – to drive individual and business results. Founded in 2012, Degreed is headquartered in Pleasanton, California, with users spanning 191 countries.
Learn more about Degreed: Website | YouTube | LinkedIn | Twitter
About Learn In
Learn In helps companies establish talent academies that steer all the resources needed for building a highly skilled workforce. HR, Talent and L&D leaders use Learn In to modernize access to learning budgets and world-class programs, and to simplify the delivery of custom programs to employee groups. Learn In’s core features include a tuition benefits manager, a prepaid learning stipend card, a world-class program marketplace and custom program builder, and dedicated coaching. Now every employee can build deeper skills precisely aligned to company needs. Co-founded by the founders of Degreed, Learn In is backed by leading edtech & future-of-work investors, including Firework Ventures, Kickstart Fund, Album, GSV, and Village Global, and has been covered in CNBC, USA Today, EdTechReview, EdSurge, Fast Company, and Techcrunch.
Learn more about Learn In: Website | LinkedIn | Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005917/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom